Winton Group’s BeOne Medicines Ltd ONC Stock Holding History

Winton Group’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,035	Closed	-$269K	–	1307
2019 Q1	$269K	Buy	+2,035	New	+$275K	0.01%	839

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Winton Group's ONC Position: Q2 2019 in Review

Winton Group sold out of BeOne Medicines Ltd (ONC) in Q2 2019, closing a stake of 2,035 shares — an estimated $269K sold.

Winton Group first reported a position in ONC in Q1 2019 and held it in 1 quarter. The position peaked at $269K in Q1 2019. 203 funds tracked by Wall St. Rank hold ONC as of Q2 2019.

Winton Group reported no remaining BeOne Medicines Ltd position as of Q2 2019 after selling out during the quarter.
Winton Group sold 2,035 BeOne Medicines Ltd shares in Q2 2019, an estimated $269K.
Winton Group first reported a position in BeOne Medicines Ltd in Q1 2019 and held it in 1 quarter.
Winton Group's BeOne Medicines Ltd position peaked at $269K in Q1 2019.
203 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2019.

Based on Winton Group's 13F filing for Q2 2019, filed 8 Jul 2019.